{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:49:26Z","timestamp":1785761366151,"version":"3.56.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41585-026-01125-y","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:18:06Z","timestamp":1769098686000},"page":"497-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ctDNA-guided treatment decisions in muscle-invasive bladder cancer"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7061-9851","authenticated-orcid":false,"given":"Lars","family":"Dyrskj\u00f8t","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"1125_CR1","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. 391, 1773\u20131786 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41585-025-01023-9","volume":"22","author":"SV Lindskrog","year":"2025","unstructured":"Lindskrog, S. V. et al. Circulating tumour DNA and circulating tumour cells in bladder cancer \u2014 from discovery to clinical implementation. Nat. Rev. Urol. 22, 590\u2013608 (2025).","journal-title":"Nat. Rev. Urol."},{"key":"1125_CR3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen, E. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clin. Oncol. 37, 1547\u20131557 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1125_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595, 432\u2013437 (2021).","journal-title":"Nature"},{"key":"1125_CR5","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","volume":"393","author":"T Powles","year":"2025","unstructured":"Powles, T. et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N. Engl. J. Med. 393, 2395\u20132408 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR6","doi-asserted-by":"publisher","unstructured":"Dyrskj\u00f8t, L. et al. ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial.Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.12.018 (2026).","DOI":"10.1016\/j.annonc.2025.12.018"},{"key":"1125_CR7","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.1016\/j.cell.2025.10.020","volume":"188","author":"JRM Black","year":"2025","unstructured":"Black, J. R. M. et al. Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction. Cell 188, 7083\u20137098.e18 (2025).","journal-title":"Cell"},{"key":"1125_CR8","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1056\/NEJMe2514185","volume":"393","author":"L Dyrskj\u00f8t","year":"2025","unstructured":"Dyrskj\u00f8t, L. ctDNA-guided therapy in bladder cancer - ready? N. Engl. J. Med. 393, 2470\u20132471 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4503","author":"T Powles","year":"2025","unstructured":"Powles, T. et al. Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4503 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1125_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.euo.2025.03.005","volume":"8","author":"A Masson-Lecomte","year":"2025","unstructured":"Masson-Lecomte, A. et al. Challenges in defining clinical complete response to systemic therapy in muscle-invasive bladder cancer: insights from the EORTC STARBURST project. Eur. Urol. Oncol. 8, 603\u2013607 (2025).","journal-title":"Eur. Urol. Oncol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01125-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01125-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01125-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:03:25Z","timestamp":1785758605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01125-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01125-y","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"22 January 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.D. has sponsored research agreements with C2i Genomics, Natera, AstraZeneca, Photocure and Ferring and serves in an advisory\/consulting role for Ferring, MSD, Cystotech and UroGen. L.D. has received speaker honoraria from AstraZeneca, Pfizer and Roche, as well as travel support from MSD.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}